SCHEMBL1337068

SCHEMBL1337068

CC(O)c1nc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)cs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 4/20 0.39
▸ EIF4E P06730 1/20 0.38
▸ CNR1 P21554 12/20 0.37
▸ CNR2 P34972 11/20 0.37
▸ KDM4E B2RXH2 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ CRHBP P24387 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ CRHR2 Q13324 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GABRA1 P14867 2/20 0.35
▸ ADRA2C P18825 2/20 0.35
▸ SLC6A3 Q01959 2/20 0.35
▸ EGFR P00533 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337141 0.89 EIF4E (0.36) IDH1EIF4ECNR1CNR2KDM4E
SCHEMBL4716844 0.87 EIF4E (0.37) IDH1EIF4ECNR1CNR2KDM4E
SCHEMBL1339432 0.86 CNR1 (0.40) EIF4ECNR1CNR2KDM4ENPC1
SCHEMBL1336976 0.86 TRIM24 (0.41) EIF4ECNR1CNR2KDM4ENPC1
SCHEMBL1339184 0.86 EIF4E (0.38) EIF4ECNR1CNR2KDM4ENPC1
SCHEMBL3256818 0.85 EIF4E (0.39) EIF4ECNR1CNR2KDM4ENPC1
SCHEMBL1339176 0.85 EIF4E (0.39) EIF4ECNR1CNR2KDM4ENPC1
SCHEMBL1339161 0.85 EIF4E (0.39) EIF4ECNR1CNR2KDM4ENPC1
SCHEMBL1339440 0.84 IDH1 (0.34) IDH1EIF4ECNR1CNR2KDM4E
SCHEMBL1339436 0.84 EIF4E (0.38) EIF4ECNR1CNR2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 IDH1 142/4885EIF4E 1083/4885CNR1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback